VRXA$1.05+1.93%
Veraxa Biotech AG - Post de-SPAC
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: DEExchange: Nasdaq
Mkt Cap:$148.46M
Float & O/S:
Inst Own:
DilutionScan read 26 of Veraxa Biotech AG - Post de-SPAC's SEC filings and found 3 warrant series, 1 convertible, 1 equity line, 2 S-1 registrations and 3 completed offerings on file for VRXA. The latest dilution event on file is a registration statement on Aug 6, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
VRXA
Pre-revenue biotech securing cash runway
Snapshot
Veraxa Biotech is a clinical-stage company developing cancer therapies. Following its merger with Voyager Acquisition Corp, the company reported a FY 2025 net loss of CHF 66.6 million, largely due to CHF 52.7 million in stock-based compensation.
What's Happening Right Now
- : VRXA issued a business update outlining a strategic pivot to focus resources on its proprietary BiTAC platform and monetize non-core assets to fund growth.
- : The company partnered with ATUM to initiate cell line development for its lead BiTAC-TCE program, aiming to advance the candidate toward regulatory submission.
- : VRXA expanded its R&D hub in Heidelberg, Germany, increasing laboratory space by over 60% to support its advancing programs.
- : The company established proof-of-concept for its BiTAC-ADC technology platform, demonstrating the ability to discriminate between cancer and healthy cells.
